Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Csl Ltd ADR (CSLLY)

Csl Ltd ADR (CSLLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Csl Ltd ADR 655 Elizabeth Street Melbourne C3 3000 AUS

www.csl.com Employees: 29,904 P: 61-3-9389-1911

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company's operating segments consists of CSL Behring and bioCSL. CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. bioCSL segment manufactures, sells and distributes vaccines, antivenoms and other pharmaceutical products primarily in Australia and New Zealand; as well as also manufactures and markets in vitro diagnostic products through Immunohaematology. It operates primarily in Germany, Switzerland and the United States. CSL Ltd. is headquartered in Parkville, Australia.

Key Statistics

Overview:

Market Capitalization, $K 58,266,696
Enterprise Value, $K 67,607,696
Shares Outstanding, K 970,303
Annual Sales, $ 15,558 M
Annual Net Income, $ 3,002 M
EBIT, $ 0 K
EBITDA, $ 5,151 M
60-Month Beta 0.77
% of Institutional Shareholders 0.03%
Float, K 970,303
% Float 100.00%
Short Volume Ratio 0.55

Growth:

1-Year Return -30.60%
3-Year Return -38.21%
5-Year Return -45.72%
5-Year Revenue Growth 70.02%
5-Year Earnings Growth 44.16%
5-Year Dividend Growth 50.59%

Per-Share Information:

Next Earnings Date 01/01/70
Earnings Per Share ttm 0.00
Annual Dividend & Yield 1.36 (2.26%)
Annual Dividend & Yield (Fwd) 1.52 (2.49%)
Most Recent Dividend 0.760 on 09/10/25
Next Ex-Dividends Date 09/10/25
Dividend Payable Date 10/10/25
Dividend Payout Ratio 0.00%

CSLLY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 17.57
Price/Earnings to Growth 2.04
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 19.30%
Debt/Equity 0.54
Price/Sales 3.80
Price/Cash Flow 13.94
Price/Book 2.76
Book Value/Share 22.11
Interest Coverage 9.31

CSLLY Dividends

Date Value
09/10/25 $0.7600
03/11/25 $0.6000
09/10/24 $0.6750
03/11/24 $0.5450
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar